Precision medicine to prevent glaucoma-related blindness

Sayoko E. Moroi, David M. Reed, David S. Sanders, Ahmed Almazroa, Lawrence Kagemann, Neil Shah, Nakul Shekhawat, Julia E. Richards

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT FINDINGS: The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.

Original languageEnglish (US)
Pages (from-to)187-198
Number of pages12
JournalCurrent opinion in ophthalmology
Volume30
Issue number3
DOIs
StatePublished - May 1 2019
Externally publishedYes

Fingerprint

Precision Medicine
Blindness
Glaucoma
Genome-Wide Association Study
Veins
Biomarkers
Alleles
Head
Technology
N,N-dimethyl-3,3-diphenyl-1-methylallylamine
Visual Field Tests
Trabeculectomy
Optical Coherence Tomography
Anterior Chamber
Angiography
Epidemiology
Catheters
Demography
Clinical Trials
Guidelines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Moroi, S. E., Reed, D. M., Sanders, D. S., Almazroa, A., Kagemann, L., Shah, N., ... Richards, J. E. (2019). Precision medicine to prevent glaucoma-related blindness. Current opinion in ophthalmology, 30(3), 187-198. https://doi.org/10.1097/ICU.0000000000000564

Precision medicine to prevent glaucoma-related blindness. / Moroi, Sayoko E.; Reed, David M.; Sanders, David S.; Almazroa, Ahmed; Kagemann, Lawrence; Shah, Neil; Shekhawat, Nakul; Richards, Julia E.

In: Current opinion in ophthalmology, Vol. 30, No. 3, 01.05.2019, p. 187-198.

Research output: Contribution to journalReview article

Moroi, SE, Reed, DM, Sanders, DS, Almazroa, A, Kagemann, L, Shah, N, Shekhawat, N & Richards, JE 2019, 'Precision medicine to prevent glaucoma-related blindness', Current opinion in ophthalmology, vol. 30, no. 3, pp. 187-198. https://doi.org/10.1097/ICU.0000000000000564
Moroi SE, Reed DM, Sanders DS, Almazroa A, Kagemann L, Shah N et al. Precision medicine to prevent glaucoma-related blindness. Current opinion in ophthalmology. 2019 May 1;30(3):187-198. https://doi.org/10.1097/ICU.0000000000000564
Moroi, Sayoko E. ; Reed, David M. ; Sanders, David S. ; Almazroa, Ahmed ; Kagemann, Lawrence ; Shah, Neil ; Shekhawat, Nakul ; Richards, Julia E. / Precision medicine to prevent glaucoma-related blindness. In: Current opinion in ophthalmology. 2019 ; Vol. 30, No. 3. pp. 187-198.
@article{cced266b2f9d4ac9b0b2a5ce6df08223,
title = "Precision medicine to prevent glaucoma-related blindness",
abstract = "PURPOSE OF REVIEW: Approximately 10{\%} of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT FINDINGS: The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.",
author = "Moroi, {Sayoko E.} and Reed, {David M.} and Sanders, {David S.} and Ahmed Almazroa and Lawrence Kagemann and Neil Shah and Nakul Shekhawat and Richards, {Julia E.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/ICU.0000000000000564",
language = "English (US)",
volume = "30",
pages = "187--198",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Precision medicine to prevent glaucoma-related blindness

AU - Moroi, Sayoko E.

AU - Reed, David M.

AU - Sanders, David S.

AU - Almazroa, Ahmed

AU - Kagemann, Lawrence

AU - Shah, Neil

AU - Shekhawat, Nakul

AU - Richards, Julia E.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - PURPOSE OF REVIEW: Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT FINDINGS: The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.

AB - PURPOSE OF REVIEW: Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT FINDINGS: The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.

UR - http://www.scopus.com/inward/record.url?scp=85064283265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064283265&partnerID=8YFLogxK

U2 - 10.1097/ICU.0000000000000564

DO - 10.1097/ICU.0000000000000564

M3 - Review article

VL - 30

SP - 187

EP - 198

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 3

ER -